CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age14-75
SponsorMingzhi Zhang
About this trial
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The participant has given informed consent and signed the consent form, and is willing and capable of complying with the scheduled visits, study treatment, laboratory examinations, and other trial procedures.
Anti-CD20 monoclonal antibodies
Combination chemotherapy containing anthracyclines.
Age 14-75 years (inclusive), both male and female.
Disqualifiers
History of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) class III or IV heart failure, cardiovascular intervention (angioplasty or stenting), myocardial infarction, unstable angina, or other clinically significant heart diseases.
History of severe pulmonary dysfunction.
Concurrent advanced malignant tumors.
Concurrent systemic fungal, bacterial, viral, or other infections that cannot be effectively controlled.
Trial design
Design model
Single group
Treatments tested in this trial
CAR-T Therapy
Biological/VaccineCAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: TreatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
objective response rate(ORR)
evaluate the efficacy of CAR-T cell infusion for the treatment of relapsed/refractory malignant hematological tumors
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Mingzhi Zhang
Lead sponsor
Zhengzhou University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: